ChemMedChem,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 31, 2024
Abstract
Nuclear
factor
erythroid
2‐related
(Nrf2)
is
a
cytoprotective
transcription
that
induces
the
of
genes
responsible
for
cell's
response
to
oxidative
stress.
While
Nrf2
activation
has
led
development
clinically
relevant
therapeutics,
oncogenic
role
in
proliferation
cancer
cells
underscored
complex
nature
and
necessity
inhibitors.
Although
application
inhibitors
appears
limited
as
anticancer
agents,
recent
studies
have
begun
pinpoint
impairment
autophagy
diseases
cellular
marker
shifts
from
protective
deleterious
state.
Therefore,
cytoplasmic
accumulation
can
lead
lipid
hydroperoxides
and,
ultimately,
ferroptosis.
However,
some
aimed
at
elucidating
non‐cancer
yielded
conflicting
results,
attributed
differences
approaches
used
inhibit
or
activate
Nrf2,
well
variations
vitro
and/or
vivo
disease
models.
Overall,
these
results
highlight
deeper
evaluation
Nrf2′s
diseases,
especially
chronic
diseases.
In
this
review,
we
discuss
where
inhibition
holds
potential
beneficial
therapeutic
effects
summarize
recently
reported
exploiting
medicinal
chemistry
suitable
targeting
factors
like
Nrf2.
Cell Biochemistry and Function,
Journal Year:
2024,
Volume and Issue:
42(4)
Published: June 1, 2024
Currently,
challenges
such
as
chemotherapy
resistance,
resulting
from
preoperative
and
postoperative
chemotherapy,
recurrence,
poor
bone
regeneration
quality,
are
becoming
increasingly
prominent
in
osteosarcoma
(OS)
treatment.
There
is
an
urgent
need
to
find
more
effective
ways
address
these
issues.
Ferroptosis
a
novel
form
of
iron-dependent
programmed
cell
death,
distinct
other
forms
death.
In
this
paper,
we
summarize
how,
through
the
three
major
defense
systems
ferroptosis,
not
only
can
substances
traditional
Chinese
medicine,
antitumor
drugs,
nano-drug
carriers
induce
ferroptosis
OS
cells,
but
they
also
be
combined
with
immunotherapy,
differentiation
therapy,
treatment
modalities
significantly
enhance
sensitivity
inhibit
tumor
growth.
Thus,
holds
great
potential
treating
OS,
offering
choices
possibilities
for
future
clinical
interventions.
ChemMedChem,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 31, 2024
Abstract
Nuclear
factor
erythroid
2‐related
(Nrf2)
is
a
cytoprotective
transcription
that
induces
the
of
genes
responsible
for
cell's
response
to
oxidative
stress.
While
Nrf2
activation
has
led
development
clinically
relevant
therapeutics,
oncogenic
role
in
proliferation
cancer
cells
underscored
complex
nature
and
necessity
inhibitors.
Although
application
inhibitors
appears
limited
as
anticancer
agents,
recent
studies
have
begun
pinpoint
impairment
autophagy
diseases
cellular
marker
shifts
from
protective
deleterious
state.
Therefore,
cytoplasmic
accumulation
can
lead
lipid
hydroperoxides
and,
ultimately,
ferroptosis.
However,
some
aimed
at
elucidating
non‐cancer
yielded
conflicting
results,
attributed
differences
approaches
used
inhibit
or
activate
Nrf2,
well
variations
vitro
and/or
vivo
disease
models.
Overall,
these
results
highlight
deeper
evaluation
Nrf2′s
diseases,
especially
chronic
diseases.
In
this
review,
we
discuss
where
inhibition
holds
potential
beneficial
therapeutic
effects
summarize
recently
reported
exploiting
medicinal
chemistry
suitable
targeting
factors
like
Nrf2.